Staff editor
The purpose of the new company is to help scientists worldwide understand how the microbiome influences health and well-being– from humans and animals to plants and the environment.
VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis
George Paraskevakos, Executive Director at International Probiotics Association, discusses the future of the microbiome space.
Specific probiotic strains can improve stress-related parameters in mothers after delivery.
Iris Dothan, from Rabin Medical Center, Israel, talks about the profiling of patient with pouchitis in order to determine the benefits from microbiome manipulation.
Jean-Luc Marsat, CEO & Chairman at EverImmune, discusses the research EverImmune carries out in oncology.
Pilar Manrique Ronquillo, Research Scientist at Microviable Therapeuthics, talks about the donor-based microbiome therapeutic products research and development.
MaaT033 (capsule), which is being developed as an adjunctive and maintenance therapy to improve overall survival in allo-HSCT, has received orphan drug designation (ODD) status from the European Medicines Agency…
New Study Demonstrates Positive Effects of NORDBIOTIC Probiotic Strains on Irritable Bowel Syndrome (IBS) in Adult Patient.
Elisa Cirillo, team lead research data manager at The Hyve, talks about the importance of having high quality data and strong tools to improve the microbiome research and business.
